| Literature DB >> 33489151 |
Mohamad Y Khatib1, Karimulla S Shaik1, Amna A Ahmed1, Mohammad A Alwraidat1, Ahmed S Mohamed1, Mohamad R Abou Kamar2, Mouhammad Z Sharaf Eldean3, Bashar K Aldaraiseh3, Abdulqadir J Nashwan1.
Abstract
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.Entities:
Keywords: COVID‐19; cytomegalovirus colitis; double‐barrel colostomy; lower gastrointestinal bleeding; tocilizumab
Year: 2020 PMID: 33489151 PMCID: PMC7813092 DOI: 10.1002/ccr3.3487
Source DB: PubMed Journal: Clin Case Rep ISSN: 2050-0904